The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Status:
Recruiting
Trial end date:
2022-10-28
Target enrollment:
Participant gender:
Summary
Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have
participated in a previous parent study to treat advanced malignancies.